- Home
- IMCR vs ARR Comparison
IMCR vs ARR Comparison
Compare IMCR & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ARR
- Stock Information
- Founded
- IMCR 2008
- ARR 2008
- Country
- IMCR United Kingdom
- ARR United States
- Employees
- IMCR N/A
- ARR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ARR Real Estate Investment Trusts
- Sector
- IMCR Health Care
- ARR Real Estate
- Exchange
- IMCR Nasdaq
- ARR Nasdaq
- Market Cap
- IMCR 1.5B
- ARR 1.4B
- IPO Year
- IMCR 2021
- ARR N/A
- Fundamental
- Price
- IMCR $31.34
- ARR $16.47
- Analyst Decision
- IMCR Buy
- ARR Hold
- Analyst Count
- IMCR 10
- ARR 5
- Target Price
- IMCR $58.13
- ARR $21.00
- AVG Volume (30 Days)
- IMCR 560.7K
- ARR 2.0M
- Earning Date
- IMCR 08-07-2025
- ARR 07-23-2025
- Dividend Yield
- IMCR N/A
- ARR 17.50%
- EPS Growth
- IMCR N/A
- ARR N/A
- EPS
- IMCR N/A
- ARR N/A
- Revenue
- IMCR $333,581,000.00
- ARR $44,778,000.00
- Revenue This Year
- IMCR $26.82
- ARR $532.77
- Revenue Next Year
- IMCR $8.15
- ARR $15.62
- P/E Ratio
- IMCR N/A
- ARR N/A
- Revenue Growth
- IMCR 25.75
- ARR 41.14
- 52 Week Low
- IMCR $23.15
- ARR $13.18
- 52 Week High
- IMCR $41.54
- ARR $21.93
- Technical
- Relative Strength Index (RSI)
- IMCR 40.28
- ARR 50.17
- Support Level
- IMCR $35.10
- ARR $16.16
- Resistance Level
- IMCR $37.56
- ARR $16.93
- Average True Range (ATR)
- IMCR 1.74
- ARR 0.26
- MACD
- IMCR -0.79
- ARR -0.02
- Stochastic Oscillator
- IMCR 0.75
- ARR 50.53
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.